Nasdaq

Pfizer to Reimburse BioNTech for COVID Vaccine Royalty Settlements

BioNTech (BNTX) has reached settlement agreements with the U.S. National Institutes of Health (NIH) and the University of Pennsylvania over royalties tied to its COVID-19 vaccine, resolving disputes ...
C&ENOpinion

Editorial: Skepticism—and success—matters on AI and vaccines

Recently, University of Cambridge and DIOSynVax researchers published the results of the first human clinical trial of a ...

BioNTech COVID-19 vaccines coming to Taiwan, Chinese agent says

TAIPEI -The Chinese sales agent for Germany's BioNTech SE said on Sunday it had signed a deal to provide 10 million COVID-19 ...
Investopedia

BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...
Benzinga.com

BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3

BioNTech's Q3 revenue rose to €1.244 billion ($1.36 billion), driven by earlier COVID-19 vaccine approvals. Q3 net profit climbed to €198.1 million, with EPS increasing to 81 cents from 66 cents YoY.
Reuters

BioNTech sued by UPenn over COVID-19 vaccine patent royalties

Aug 6 (Reuters) - The University of Pennsylvania has sued German biotechnology firm BioNTech (22UAy.DE), opens new tab in Pennsylvania federal court, accusing the company of underpaying royalties for ...

Cancer vaccines based on mRNA advance, despite US cuts

By Julie Steenhuysen CHICAGO, June 9 (Reuters) - Treatments based on the same mRNA technology that delivered COVID-19 ...
Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
MM&M

BioNTech, Regeneron tout mRNA cancer vaccine’s Phase 2 trial results

A combination mRNA cancer vaccine from BioNTech and Regeneron may be one step closer to actualization based on initial Phase 2 results unveiled Tuesday. The mRNA-based vaccine, BNT111, in combination ...
Health Affairs

COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...
JD Supra

BioNTech Sues Moderna over mRNA Vaccine Technology

One of the paradoxically beneficial consequences of the COVID pandemic was that even without the compulsory aspects of the vaccine patent waiver proposed by certain WTO member states (Brazil, India, ...
U.S. News & World Report

BioNTech's Q2 Revenues Double on Higher COVID Vaccine Sales

FRANKFURT (Reuters) -German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine ...